Human Immunoglobulin G

CHEMBL1201599 Phase 4 Onaylandı Unknown

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This preparation contains protective antibodies derived from donated human plasma, used to supplement or replace the immune defenses of people who cannot make adequate antibodies on their own. It is administered to treat immune deficiencies and certain autoimmune or inflammatory conditions.

Terapötik Alanlar

Immunology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This preparation contains protective antibodies derived from donated human plasma, used to supplement or replace the immune defenses of people who cannot make adequate antibodies on their own. It is administered to treat immune deficiencies and certain autoimmune or inflammatory conditions.

Yes, Human Immunoglobulin G is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201599. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Human Immunoglobulin G PillFYI'da

Hızlı Veriler

Eş Anlamlılar: 9

Dış Bağlantılar

ChEMBL CHEMBL1201599

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.